To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Pulmonary Arterial Hypertension - Pipeline Review, Q2 2011
Global Markets Direct’s, 'Pulmonary Arterial Hypertension - Pipeline Review, Q2 2011', provides an overview of the Pulmonary Arterial Hypertension therapeutic pipeline. This report provides information on the therapeutic development for Pulmonary Arterial Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pulmonary Arterial Hypertension. 'Pulmonary Arterial Hypertension - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Pulmonary Arterial Hypertension.
- A review of the Pulmonary Arterial Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Pulmonary Arterial Hypertension pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Pulmonary Arterial Hypertension.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension pipeline depth and focus of Pulmonary Arterial Hypertension therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
|Pharmacy / Drugs||Market study|
Order market study
Order the market study at markt-studie.de
This is where you can add this market study to your personal favourites.
- 1PT Bristol-Myers Squibb Indonesia Tbk (SQBI) - Financial and Strategic SWOT Analysis Review
- 2Cipla Ltd. (CIPLA) - Financial and Strategic SWOT Analysis Review
- 3Herbalife Ltd. (HLF) - Financial and Strategic SWOT Analysis Review
- 4Tiger Brands Ltd (TBS) - Financial and Strategic SWOT Analysis Review
- 5Asiri Hospital PLC (ASIR) - Financial and Strategic SWOT Analysis Review
- 6Shanghai Kehua Bio-engineering Co., Ltd. (002022) - Financial and Strategic SWOT Analysis Review
- 7Beximco Pharmaceuticals Ltd. (BXP) - Financial and Strategic SWOT Analysis Review
- 8Sanofi-aventis Pakistan limited (SAPL) - Financial and Strategic SWOT Analysis Review
- 9Cambodia Pharmaceuticals and Healthcare Report Q1 2012
- 10Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market